MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1

Zha,Zhongming; Li,Jie

doi:10.3892/ijmm.2020.4729

MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1

Authors:
- Zhongming Zha
- Jie Li
View Affiliations

Affiliations: Department of Hepato‑Pancreato‑Biliary‑Hernial Surgery Ward I, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan 471000, P.R. China, Department of Hepatobiliary Surgery, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China
Published online on: September 16, 2020 https://doi.org/10.3892/ijmm.2020.4729
Pages: 1849-1861
Copyright: © Zha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To date, the role of hematopoietic‑substrate‑1‑associated protein X‑1 (HAX1) in liver cancer is rarely studied. The present study explored the role of HAX1 in liver cancer. The association between HAX1 expression and survival of patients with liver cancer was analyzed by a log‑rank test. The target genes for HAX1 was predicted by TargetScan and verified by a dual‑luciferase reporter assay. The protein and mRNA expressions of HAX1 in liver cancer and adjacent non‑cancerous tissues were examined by immunohistochemistry and reverse transcription‑quantitative PCR (RT‑qPCR). The transfection efficiency of HAX1, small interfering RNA against HAX1, microRNA (miR)‑125a mimics, miR‑125a inhibitor, miR‑223 mimics and miR‑223 inhibitor in liver cancer cells was determined by RT‑qPCR. The expression of HAX1, p53, VEGF, epithelial‑to‑mesenchymal transition (EMT)‑related markers (E‑cadherin, N‑cadherin and vimentin) in the cancer cells were determined by western blotting and RT‑qPCR. Cell viability, migration, invasion and colony formation rates were determined by Cell Counting Kot‑8, wound healing, Transwell and colony formation assays, respectively. The results showed that high expression of HAX1 in liver cancer was found relate to poor prognosis in patients with liver cancer, and upregulation of HAX1 expression in liver cancer tissues was related to lower overall survival. miR‑125a‑5p directly binds to HAX1. Upregulation of miR‑125a‑5p expression inhibited cell viability, migration, invasion and colony formation of SK‑Hep1 cells and reduced the expression of HAX1, VEGF, N‑cadherin and vimentin, but increased cell apoptosis and the expression of p53 and E‑cadherin. However, the effects miR‑125a‑5p upregulation were partially reversed by SK‑Hep1 cells with HAX1 overexpression. Downregulated miR‑125a‑5p in SNU‑387 cells produced opposite effects, which was partially reversed by HAX silencing. In conclusion, miR‑125a‑5p suppresses liver cancer growth via targeting HAX1 and concurrently modulating the expression of p53 and VEGF and EMT‑related markers.

View Figures

View References

1	Costentin C: Hepatocellular carcinoma surveillance. Presse Med. 46:381–385. 2017.In French. View Article : Google Scholar : PubMed/NCBI
2	Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhu ZX, Huang JW, Liao MH and Zeng Y: Treatment strategy for hepatocellular carcinoma in China: Radiofrequency ablation versus liver resection. Jpn J Clin Oncol. 46:1075–1080. 2016.PubMed/NCBI
4	Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y, Huang F, Wang J, Peng L and Luo H: MiR-15b mediates liver cancer cells proliferation through targeting BCL-2. Int J Clin Exp Pathol. 8:15677–15683. 2015.
6	Liu CY, Chen KF and Chen PJ: Treatment of liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015. View Article : Google Scholar : PubMed/NCBI
7	Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
8	Guo M, Zhang H, Zheng J and Liu Y: Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer. 11:2008–2021. 2020. View Article : Google Scholar : PubMed/NCBI
9	Balcerak A, Trebinska-Stryjewska A, Wakula M, Chmielarczyk M, Smietanka U, Rubel T, Konopinski R, Macech-Klicka E, Zub R and Grzybowska EA: HAX1 impact on collective cell migration, cell adhesion, and cell shape is linked to the regulation of actomyosin contractility. Mol Biol Cell. 30:3024–3036. 2019. View Article : Google Scholar : PubMed/NCBI
10	Bidwell PA, Liu GS, Nagarajan N, Lam CK, Haghighi K, Gardner G, Cai WF, Zhao W, Mugge L, Vafiadaki E, et al: HAX-1 regulates SERCA2a oxidation and degradation. J Mol Cell Cardiol. 114:220–233. 2018. View Article : Google Scholar :
11	Fadeel B and Grzybowska E: HAX-1: A multifunctional protein with emerging roles in human disease. Biochim Biophys Acta. 1790:1139–1148. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wei XJ, Li SY, Yu B, Chen G, Du JF and Cai HY: Expression of HAX-1 in human colorectal cancer and its clinical significance. Tumour Biol. 35:1411–1415. 2014. View Article : Google Scholar
13	Li X, Li T, You B, Shan Y, Shi S, Cao X and Qian L: Expression and function of HAX-1 in human cutaneous squamous cell carcinoma. J Cancer. 6:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
14	You Y, Yao H, You B, Li X, Ni H, Shi S, Shan Y and Cao X: Clinical significance of HAX-1 expression in laryngeal carcinoma. Auris Nasus Larynx. 42:299–304. 2015. View Article : Google Scholar : PubMed/NCBI
15	Feng X, Kwiecinska A, Rossmann E, Bottai M, Ishikawa T, Patarroyo M, Österborg A, Porwit A, Zheng C and Fadeel B: HAX-1 overexpression in multiple myeloma is associated with poor survival. Br J Haematol. 185:179–183. 2019. View Article : Google Scholar
16	Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S, Weinreb P, Hart IR and Marshall JF: HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res. 67:5275–5284. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Huo X, Cao Z, Xu H, Zhu J, Qian L, Fu H and Xu B: HAX-1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation. Int J Clin Exp Pathol. 8:8099–8106. 2015.PubMed/NCBI
18	Banerjee A, Saito K, Meyer K, Banerjee S, Ait-Goughoulte M, Ray RB and Ray R: Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. J Virol. 83:9663–9671. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu W, Cui Z and Zan X: Identifying cancer-related microRNAs based on subpathways. IET Syst Biol. 12:273–278. 2018. View Article : Google Scholar : PubMed/NCBI
20	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gandhi NS, Tekade RK and Chougule MB: Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J Control Release. 194:238–256. 2014. View Article : Google Scholar : PubMed/NCBI
22	Gallach S, Calabuig-Farinas S, Jantus-Lewintre E and Camps C: MicroRNAs: Promising new antiangiogenic targets in cancer. Biomed Res Int. 2014:8784502014. View Article : Google Scholar : PubMed/NCBI
23	Li E, Ji P, Ouyang N, Zhang Y, Wang XY, Rubin DC, Davidson NO, Bergamaschi R, Shroyer KR, Burke S, et al: Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities. Int J Oncol. 45:587–594. 2014. View Article : Google Scholar : PubMed/NCBI
24	Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M: MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 17:2725–2733. 2011. View Article : Google Scholar : PubMed/NCBI
25	Li G, Zhang W, Gong L and Huang X: MicroRNA 125a-5p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by downregulation of ErbB3. Oncol Res. 27:449–458. 2019. View Article : Google Scholar
26	Cai M, Chen Q, Shen J, Lv C and Cai L: Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. J Cell Mol Med. 22:4721–4731. 2018. View Article : Google Scholar : PubMed/NCBI
27	Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012. View Article : Google Scholar : PubMed/NCBI
28	Menyhárt O, Nagy Á and Győrffy B: Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 5:1810062018. View Article : Google Scholar
29	Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang Y, Zhang L, Li P, Cui X, Chen L, et al: Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma. . Exp Mol Pathol. 87:167–172. 2009. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
31	Sheng C and Ni Q: Expression of HAX1 and Ki-67 in breast cancer and its correlations with patient's clinicopathological characteristics and prognosis. Int J Clin Exp Med. 8:20904–20910. 2015.
32	Li M, Tang Y, Zang W, Xuan X, Wang N, Ma Y, Wang Y, Dong Z and Zhao G: Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma. Diagn Pathol. 8:472013.PubMed/NCBI
33	Deng X, Song L, Wei Y and Guo XB: Analysis of the expression of HAX-1 gene in human glioma. Neurosci Lett. 657:189–193. 2017. View Article : Google Scholar : PubMed/NCBI
34	Wu Z, Ai X, Hu H, Wang S, Wang Y, Kang F, Ouyang C and Zhu J: Hematopoietic-substrate-1 associated protein X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and angiogenesis through Akt. Cancer Biol Ther. 20:1223–1233. 2019. View Article : Google Scholar : PubMed/NCBI
35	Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M and Dolznig H: In vitro cell migration and invasion assays. Mutat Res. 752:10–24. 2013. View Article : Google Scholar
36	Duff D and Long A: Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 35:250–255. 2017. View Article : Google Scholar : PubMed/NCBI
37	Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ and Ma WL: High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 8:3076–3082. 2015.PubMed/NCBI
38	Shan H, Zhou X and Chen C: MicroRNA214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2. Mol Med Rep. 20:1459–1467. 2019.PubMed/NCBI
39	Yan L, Yu MC, Gao GL, Liang HW, Zhou XY, Zhu ZT, Zhang CY, Wang YB and Chen X: MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J Cell Biochem. 119:8773–8783. 2018. View Article : Google Scholar : PubMed/NCBI
40	Yang X, Qiu J, Kang H, Wang Y and Qian J: miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA. Cancer Manag Res. 10:5839–5853. 2018. View Article : Google Scholar : PubMed/NCBI
41	Zhang Y, Zhang D, Lv J, Wang S and Zhang Q: MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. Biomed Pharmacother. 108:1039–1047. 2018. View Article : Google Scholar : PubMed/NCBI
42	Zhong L, Sun S, Shi J, Cao F, Han X and Chen Z: MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3. Tumour Biol. 39:10104283176975792017. View Article : Google Scholar : PubMed/NCBI
43	Fu Y and Cao F: MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma. Onco Targets Ther. 8:3827–3835. 2015. View Article : Google Scholar
44	Tang L, Zhou L, Wu S, Shi X, Jiang G, Niu S and Ding D: miR-125a-5p inhibits colorectal cancer cell epithelial-mesenchymal transition, invasion and migration by targeting TAZ. Onco Targets Ther. 12:3481–3489. 2019. View Article : Google Scholar : PubMed/NCBI
45	Qin X, Wan Y, Wang S and Xue M: MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. Drug Des Devel Ther. 10:71–79. 2015.
46	Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, Caraglia M and Russo A: MicroRNA-125a-5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepato-cellular carcinoma cells. J Cell Physiol. 232:1907–1913. 2017. View Article : Google Scholar
47	Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 57:1055–1067. 2013. View Article : Google Scholar
48	Yu YF, Zhang Y, Shen N, Zhang RY and Lu XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
49	Zhou X, Wu W, Zeng A, Nie E, Jin X, Yu T, Zhi T, Jiang K, Wang Y, Zhang J and You Y: MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53. Oncotarget. 8:71080–71094. 2017. View Article : Google Scholar : PubMed/NCBI
50	Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
51	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
52	Zhang T, Liu M, Wang C, Lin C, Sun Y and Jin D: Down-regulation of MiR-206-promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 31:3859–3863. 2011.PubMed/NCBI
53	Wu QB, Chen J, Zhu JW, Yin X, You HY, Lin YR and Zhu HQ: MicroRNA-125 inhibits RKO colorectal cancer cell growth by targeting VEGF. Int J Mol Med. 42:665–673. 2018.PubMed/NCBI
54	Jakobsen KR, Demuth C, Sorensen BS and Nielsen AL: The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
55	Xiao Z, Chen M, Yang J, Yang C, Lü X, Tian H and Liu C: MTBP regulates migration and invasion of prostate cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 39:6–12. 2019.In Chinese. PubMed/NCBI
56	Ramamurthy VP, Ramalingam S, Gediya LK and Njar VCO: The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. FEBS J. 285:1051–1063. 2018. View Article : Google Scholar : PubMed/NCBI
57	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI